PT - JOURNAL ARTICLE AU - , AU - Mohamed, Abdallah S. R. AU - Abusaif, Abdelrahman AU - He, Renjie AU - Wahid, Kareem AU - Salama, Vivian AU - Youssef, Sara AU - McDonald, Brigid A. AU - Naser, Mohamed AU - Ding, Yao AU - Salzillo, Travis C. AU - AboBakr, Moamen A. AU - Wang, Jihong AU - Lai, Stephen Y. AU - Fuller, Clifton D. TI - Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study AID - 10.1101/2022.04.18.22273782 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.18.22273782 4099 - http://medrxiv.org/content/early/2022/04/18/2022.04.18.22273782.short 4100 - http://medrxiv.org/content/early/2022/04/18/2022.04.18.22273782.full AB - Purpose/Objective(s) To determine diffusion-weighted imaging (DWI) MRI parameters associated with tumor response and oncologic outcomes in head and neck (HNC) patients treated with definitive radiation therapy (RT).Materials/Methods Eighty-six HNC patients enrolled in an active prospective imaging study at The University of Texas MD Anderson Cancer Center were included in the analysis. Patients had MRIs pre-, mid-, and post-RT completion. Inclusion criteria included adults with histologic evidence of malignant head and neck neoplasm indicated for curative-intent treatment with RT with/without chemotherapy, good performance status (ECOG score 0-2), and with no contraindications to MRI. Patients were scanned using a MAGNETOM Aera 1.5T MR scanner (Siemens Healthcare, Germany) with two large four-channel flex phased-array coils. We used fat-suppressed T2-weighted turbo spin echo sequences for tumor segmentation which were co-registered to respective DWIs for extraction of apparent diffusion coefficient (ADC) measurements. Treatment response was assessed at mid-RT and at 8-12 weeks post-RT using RECIST 1.1 criteria and was defined as: complete response (CR) vs. non-complete response (non-CR). Pre-RT ADC was correlated with RT response (CR vs. non-CR) at mid- and post-RT. The Mann-Whitney U test was used to compare ADC values between the mid-treatment CR group and the non-CR group. Recursive partitioning analysis (RPA) was performed to identify ADC threshold associated with relapse. Cox proportional hazards models were done for clinical vs. clinical and imaging parameters and internal validation was done using bootstrapping technique.Results Eighty-one patients were included in this analysis. Median follow-up was 31 months. Pre-treatment ADC was not correlated with tumor response or oncologic outcomes (P>0.05). For patients with post-RT CR, there was a significant increase in mean ADC at mid-RT compared to baseline ((1.8 ± 0.29) × 10−3 mm2/s versus (1.37 ± 0.22) × 10− 3 mm2/s, p < 0.0001), while patients with non-CR had no statistically significant increase (p >0.05). RPA identified GTV-P delta (Δ) ADCmean <7% at mid-RT as the most significant parameter associated with worse LC and RFS (p=0.01). Univariable and multivariable analysis of prognostic outcomes showed that GTV-P ΔADCmean at mid-RT ≥7% was significantly associated with better LC and RFS. The addition of ΔADCmean significantly improved the c-indices of LC and RFS models compared with standard clinical variables (0.85 vs. 0.77 and 0.74 vs. 0.68 for LC and RFS, respectively, p<0.0001 for both).Conclusion ADC change at mid-RT is a strong predictor of oncologic outcomes in HNC patients. Patients with no significant increase of primary tumor site ADC at mid-RT relative to baseline values are at high risk of disease relapse. Multi-institutional data are needed for validation of our results.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03145077Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03145077 Funding StatementDr. Mohamed & Dr. Fuller received/receives funding and salary support from directly related to this project from: NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NIH/NSF NCI Smart Connected Health Program (R01CA257814). Dr. Fuller received/receives funding and salary support from directly unrelated to this project from: NCI Parent Research Project Grant (R01CA258827); NCI Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32CA261856); NIH NIDCR Exploratory/Developmental Research Grant Program (R21DE031082); National Institutes of Health (NIH) National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Program (R01CA214825); NSF/NIH Joint Initiative on Quantitative Approaches to Biomedical Big Data program (R01CA225190); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); Small Business Innovation Research Grant Program a sub-award from Oncospace, Inc. (R43CA254559); The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Initiative (OT2OD026675) sub-award; Patient-Centered Outcomes Research Institute (PCS-1609-36195) sub-award from Princess Margaret Hospital; National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). Dr. Fuller receives grant and infrastructure support from MD Anderson Cancer Center via: the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image-guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672). Dr. Fuller has received direct industry grant/in-kind support, honoraria, and travel funding from Elekta AB. TCS was supported by The University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences TL1 Program (TL1 TR003169). Dr. Lai receives funding and salary support from R01DE025248, R01DE028290, R21CA259839, NRG-HN006, and T32CA261856.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional-review board of the University of Texas MD Anderson cancer center, Houston, TX, USA gave ethical approval of this work under protocol PA16-0302. The protocol is also available at clinicaltrials.gov (NCT03145077)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.